SGS Acquires Keystone Bioanalytical
May 4, 2026
SGS has acquired Keystone Bioanalytical, a Philadelphia-based provider of bioanalytical testing services, to strengthen its end-to-end drug development lifecycle capabilities. The acquisition expands SGS’s GLP-compliant, bioanalysis-focused capacity for North American pharma and biotech clients, including LC-MS/MS method development, validation, and analysis.
- Buyers
- SGS
- Targets
- Keystone Bioanalytical
- Industry
- Healthcare Services
- Location
- Pennsylvania, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.